Vizamyl Approval History

• FDA approved: Yes (First approved October 25th, 2013)
• Brand name: Vizamyl
• Generic name: flutemetamol F 18
• Company: GE Healthcare
• Treatment for: Diagnosis and Investigation

Vizamyl (flutemetamol F 18) is a PET amyloid imaging agent for the evaluation of Alzheimer's disease or other cognitive disorders.

Development History and FDA Approval Process for Vizamyl

Date	Article
Oct 25, 2013	FDA Approves Vizamyl Brain Imaging Drug to Help Evaluate Patients for Alzheimer’s Disease, Dementia
Jan  8, 2013	GE Healthcare Announces Acceptance of Applications for Review of Investigational Imaging Agent [18F]Flutemetamol in the United States and Europe

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.